Patents by Inventor Ernestine A. Lee

Ernestine A. Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210009697
    Abstract: The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).
    Type: Application
    Filed: September 12, 2018
    Publication date: January 14, 2021
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Katherine E. Lewis, Serena Kimi Perna, Michael Carleton, Ke Xu, Penny Phillips, Dimple Pandya, Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Janine Powers, Ernestine Lee
  • Publication number: 20170349643
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Application
    Filed: June 12, 2017
    Publication date: December 7, 2017
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen K. Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin G.P. Wong, Ge Wu, Hongbing Zhang
  • Publication number: 20170283783
    Abstract: Various embodiments of the invention provide human kinases and phosphatases (KPP) polypeptides and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP.
    Type: Application
    Filed: June 15, 2017
    Publication date: October 5, 2017
    Applicant: Incyte Corporation
    Inventors: Vicki S. Kaulback, Reena Khare, Thomas W. Richardson, Joseph P. Marquis, Anita Swarnakar, April J. A. Hafalia, Shanya D. Becha, Narinder K. Chawla-Walia, Mariah R. Baughn, Soo Yeun Lee, Uyen K. Tran, Henry Yue, Danniel B. Nguyen, Michael B. Thorton, Rajagopal Gururajan, Ameena R. Gandhi, Yan Lu, Monique G. Yao, Joana X. Li, Wen Luo, Ernestine A. Lee, Craig H. Ison, Amy D. Wilson, Pei Jin, Ian J. Forsythe
  • Publication number: 20160096876
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Application
    Filed: October 7, 2015
    Publication date: April 7, 2016
    Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen K. Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
  • Patent number: 9192683
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: November 24, 2015
    Assignee: FIVE PRIME THERAPEUTICS, INC.
    Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen K. Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
  • Patent number: 9173957
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Grant
    Filed: May 29, 2013
    Date of Patent: November 3, 2015
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen K. Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
  • Publication number: 20140356342
    Abstract: Various embodiments of the invention provide human kinases and phosphatases (KPP) polypeptides and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP.
    Type: Application
    Filed: June 6, 2014
    Publication date: December 4, 2014
    Inventors: Vicki S. Kaulback, Reena Khare, Thomas W. Richardson, Joseph P. Marquis, Anita Swarnakar, April J. A. Hafalia, Shanya D. Becha, Narinder K. Chawla-Walia, Mariah R. Baughn, Soo Yeun Lee, Uyen K. Tran, Henry Yue, Danniel B. Nguyen, Michael B. Thorton, Rajagopal Gururajan, Ameena R. Gandhi, Yan Lu, Monique G. Yao, Joana X. Li, Wen Luo, Ernestine A. Lee, Craig H. Ison, Amy D. Wilson, Pei Jin, Ian J. Forsythe
  • Patent number: 8779106
    Abstract: Various embodiments of the invention provide human kinases and phosphatases (KPP) polypeptides and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: July 15, 2014
    Assignee: Incyte Corporation
    Inventors: Vicki S. Elliott, Reena Khare, Thomas W. Richardson, Joseph P. Marquis, Anita Swarnakar, April J. A. Hafalia, Shanya D. Becha, Narinder K. Chawla-Walia, Mariah R. Baughn, Soo Yeun Lee, Uyen K. Tran, Henry Yue, Danniel B. Nguyen, Michael B. Thornton, Rajagopal Gururajan, Ameena R. Gandhi, Yan Lu, Monique G. Yao, Joana X. Li, Wen Luo, Ernestine A. Lee, Ian J. Forsythe, Craig H. Ison, Amy D. Wilson, Pei Jin
  • Publication number: 20140170145
    Abstract: Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.
    Type: Application
    Filed: October 8, 2013
    Publication date: June 19, 2014
    Applicant: FIVE PRIME THERAPEUTICS, INC.
    Inventors: Dirk Behrens, Elizabeth Bosch, Stephen K. Doberstein, Robert Forgan Halenbeck, Kevin Hestir, Min Mei Huang, Ernestine Lee, Haishan Lin, Thomas Linnemann, Shannon Marshall, Justin Wong, Ge Wu, Aileen Zhou, Cindy Leo, Lewis T. Williams
  • Publication number: 20140140995
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Application
    Filed: October 8, 2013
    Publication date: May 22, 2014
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen K. Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
  • Publication number: 20130324701
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Application
    Filed: May 29, 2013
    Publication date: December 5, 2013
    Applicant: FIVE PRIME THERAPEUTICS, INC.
    Inventors: Lewis T. WILLIAMS, Elizabeth BOSCH, Stephen K. DOBERSTEIN, Kevin HESTIR, Diane HOLLENBAUGH, Ernestine LEE, Minmin QIN QIN, Ali SADRA, Justin WONG, Ge WU, Hongbing ZHANG ZHANG
  • Patent number: 8580936
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Grant
    Filed: September 7, 2011
    Date of Patent: November 12, 2013
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
  • Patent number: 8575312
    Abstract: Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: November 5, 2013
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Dirk Behrens, Elizabeth Bosch, Stephen K. Doberstein, Robert Forgan Halenbeck, Kevin Hestir, Min Mei Huang, Ernestine Lee, Haishan Lin, Thomas Linnemann, Shannon Marshall, Justin G. P. Wong, Ge Wu, Aileen Zhou, Cindy Leo, Lewis T. Williams
  • Patent number: 8501191
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: August 6, 2013
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Elizabeth Bosch, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra
  • Patent number: 8431532
    Abstract: Methods of treatment using Fzd8 extracellular domains (ECDs), Fzd8 ECD fusion molecules, and/or antibodies that bind Fzd8 are provided. Such methods include, but are not limited to, methods of treating obesity and obesity-related conditions. Fzd8 ECDs and Fzd8 ECD fusion molecules are also provided. Polypeptide and polynucleotide sequences, vectors, host cells, and compositions comprising or encoding such molecules are provided. Methods of making and using Fzd8 ECDs, Fzd8 ECD fusion molecules, and antibodies that bind Fzd8 are also provided.
    Type: Grant
    Filed: June 27, 2011
    Date of Patent: April 30, 2013
    Assignee: Five Prime Therepeutics, Inc.
    Inventors: Thomas Brennan, Ernestine Lee, Steven Smith
  • Publication number: 20130065276
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Application
    Filed: September 7, 2011
    Publication date: March 14, 2013
    Inventors: Lewis T. WILLIAMS, Elizabeth Bosch, Stephen Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
  • Publication number: 20130058942
    Abstract: Various embodiments of the invention provide human kinases and phosphatases (KPP) polypeptides and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP.
    Type: Application
    Filed: July 30, 2012
    Publication date: March 7, 2013
    Inventors: Vicki S. Elliott, Reena Khare, Thomas W. Richardson, Joseph P. Marquis, Anita Swarnakar, April J.A. Hafalia, Shanya D. Becha, Narinder K. Chawla-Walia, Mariah R. Baughn, Soo Yeun Lee, Uyen K. Tran, Henry Yue, Danniel B. Nguyen, Michael B. Thornton, Rajagopal Gururajan, Ameena R. Gandhi, Yan Lu, Monique G. Yao, Joana X. Li, Wen Luo, Ernestine A. Lee, Ian J. Forsythe, Craig H. Ison, Amy D. Wilson, Pei Jin
  • Publication number: 20120301921
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Application
    Filed: April 3, 2012
    Publication date: November 29, 2012
    Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
  • Publication number: 20120258071
    Abstract: Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.
    Type: Application
    Filed: April 13, 2012
    Publication date: October 11, 2012
    Inventors: Dirk Behrens, Elizabeth Bosch, Stephen K. Doberstein, Robert Forgan Halenbeck, Kevin Hestir, Min Mei Huang, Ernestine Lee, Haishan Lin, Thomas Linnemann, Shannon Marshall, Justin G. P. Wong, Ge Wu, Aileen Zhou, Cindy Leo, Lewis T. Williams
  • Patent number: 8263378
    Abstract: Various embodiments of the invention provide human kinases and phosphatases (KPP) polypeptides and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP.
    Type: Grant
    Filed: September 20, 2010
    Date of Patent: September 11, 2012
    Assignee: Incyte Corporation
    Inventors: Vicki S. Elliott, Reena Khare, Thomas W. Richardson, Joseph P. Marquis, Anita Swarnakar, April J. A. Hafalia, Shanya D. Becha, Narinder K. Chawla-Walia, Mariah R. Baughn, Soo Yeun Lee, Uyen K. Tran, Henry Yue, Danniel B. Nguyen, Michael B. Thornton, Rajagopal Gururajan, Ameena R. Gandhi, Yan Lu, Monique G. Yao, Joana X. Li, Wen Luo, Ernestine A. Lee, Ian J. Forsythe, Craig H. Ison, Amy D. Wilson, Pei Jin